IDEAYA Biosciences Enrolls First Patient In Phase 1 Trial Of IDE034, A Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC For Solid Tumors
Benzinga Newsdesk 8 months ago
News
Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161B7H3/PTK7 co-expressed in 30-40% of multiple solid
- Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034
- Potential as a monotherapy and in combination with proprietary PARG inhibitor, IDE161
- B7H3/PTK7 co-expressed in 30-40% of multiple solid tumor types, including lung, breast, ovarian and colorectal cancers